Anti-Hepatocellular Carcinoma Effects of Phillygenin: Integrated Network Pharmacology, Molecular Modeling, and Experimental Validation
Drug Design, Development and Therapy · 2026-11 · Volume 20 · 1-23
DOI: 10.2147/dddt.s627438 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026-11. Verfasst von Linhui Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The Central Hospital of Yongzhou, Yongzhou, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antineoplastic Agents, Phytogenic, Lignans. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, The Central Hospital of Yongzhou, Yongzhou, People's Republic of China.
- Department of Radiology, Yongzhou Hospital Affiliated to University of South China, Yongzhou, People's Republic of China.
Zitieren
APA
Chen, L., Huang, J., Wang, D., Wu, Y., & Shi, L. (2026). Anti-Hepatocellular Carcinoma Effects of Phillygenin: Integrated Network Pharmacology, Molecular Modeling, and Experimental Validation. Drug Design, Development and Therapy, Volume 20, 1-23. https://doi.org/10.2147/dddt.s627438
Vancouver
Chen L, Huang J, Wang D, Wu Y, Shi L. Anti-Hepatocellular Carcinoma Effects of Phillygenin: Integrated Network Pharmacology, Molecular Modeling, and Experimental Validation. Drug Design, Development and Therapy. 2026;Volume 20:1-23. doi:10.2147/dddt.s627438
BibTeX
@article{Chen2026,
author = {Chen, Linhui and Huang, Jiabin and Wang, Dan and Wu, Yanqiu and Shi, Linbo},
title = {Anti-Hepatocellular Carcinoma Effects of Phillygenin: Integrated Network Pharmacology, Molecular Modeling, and Experimental Validation},
journal = {Drug Design, Development and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--23},
doi = {10.2147/dddt.s627438}
}
EUVIMED